The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1533
ISSUE1533
November 6, 2017
Cotempla XR-ODT - Another Long-Acting Methylphenidate for ADHD
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Cotempla XR-ODT - Another Long-Acting Methylphenidate for ADHD
November 6, 2017 (Issue: 1533)
The FDA has approved an extended-release orally
disintegrating tablet formulation of methylphenidate
(Cotempla XR-ODT – Neos Therapeutics) for once-daily
treatment of attention-defi cit/hyperactivity
disorder (ADHD) in children 6-17 years...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.